Clinical Trials Logo

Carcinoma of Unknown Primary clinical trials

View clinical trials related to Carcinoma of Unknown Primary.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT00119314 Withdrawn - Clinical trials for Carcinoma of Unknown Primary

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Start date: July 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel and capecitabine works in treating patients with cancer of unknown primary origin.